Targeting subchondral bone for treating osteoarthritis: what is the evidence?

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 1, 2010, Pages 51-70

  Kwan Tat, Steeve ^a   Lajeunesse, Daniel ^a   Pelletier, Jean Pierre ^a   Martel Pelletier, Johanne ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

articular tissues; osteoarthritis; subchondral bone

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CATHEPSIN K INHIBITOR; CORTICOSTEROID; CYTOKINE ANTIBODY; DIACETYLRHEIN; EPHRIN; EPHRIN B2; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; ESTROGEN; GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PIASCLEDINE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RISEDRONIC ACID; SCATTER FACTOR; SOMATOMEDIN; STRONTIUM RANELATE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VITAMIN D; WNT PROTEIN;

BONE; BONE DENSITY; BONE REMODELING; CARTILAGE; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; KNEE OSTEOARTHRITIS; MESENCHYME CELL; MOLECULAR INTERACTION; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN MANIFESTATION; SUBCHONDRAL BONE;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CARTILAGE, ARTICULAR; EVIDENCE-BASED MEDICINE; HUMANS; OSTEOARTHRITIS;

EID: 74549170849     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2009.08.004     Document Type: Review

References (169)

1. Ng K.W., Romas E., Donnan L., and Findlay D.M. Bone biology. Baillieres Clin Endocrinol Metab 11 (1997) 1-22
2. Hill P.A. Bone remodelling. Br J Orthod 25 (1998) 101-107
3. Troen B.R. Molecular mechanisms underlying osteoclast formation and activation. Exp Gerontol 38 (2003) 605-614
4. Martel-Pelletier J., Lajeunesse D., and Pelletier J.P. Etiopathogenesis of osteoarthritis. In: Koopman W.J., and Moreland L.W. (Eds). Arthritis & allied conditions. A textbook of rheumatology. 15th ed. (2005), Lippincott, Williams & Wilkins, Baltimore 2199-2226
5. Carlson C.S., Loeser R.F., Jayo M.J., et al. Osteoarthritis in cynomolgus macaques: a primate model of naturally occurring disease. J Orthop Res 12 (1994) 331-339
6. Brandt K.D., Myers S.L., Burr D., and Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 34 (1991) 1560-1570
7. Hayami T., Pickarski M., Wesolowski G.A., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 50 (2004) 1193-1206
8. Pelletier J.P., Boileau C., Brunet J., et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 34 (2004) 527-538
9. Hayami T., Pickarski M., Zhuo Y., et al. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38 (2006) 234-243
10. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 8 (2006) R21
11. Pelletier J.P., Raynauld J.P., Berthiaume M.J., et al. Risk factors associated with the loss of cartilage volume on weight bearing areas in knee osteoarthritis patients assessed by quantitative MRI: a longitudinal study. Arthritis Res Ther 9 (2007) R74
12. Raynauld J.-P., Martel-Pelletier J., Berthiaume M.-J., et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 67 (2008) 683-688
13. Boileau C., Martel-Pelletier J., Abram F., et al. Magnetic resonance imaging can accurately assess the long-term progression of knee structural changes in experimental dog OA. Ann Rheum Dis 67 (2008) 926-932
14. Blumenkrantz G., Lindsey C.T., Dunn T.C., et al. A pilot, two-year longitudinal study of the interrelationship between trabecular bone and articular cartilage in the osteoarthritic knee. Osteoarthritis Cartilage 12 (2004) 997-1005
15. Beuf O., Ghosh S., Newitt D.C., et al. Magnetic resonance imaging of normal and osteoarthritic trabecular bone structure in the human knee. Arthritis Rheum 46 (2002) 385-393
16. Martig S., Boisclair J., Konar M., et al. MRI characteristics and histology of bone marrow lesions in dogs with experimentally induced osteoarthritis. Vet Radiol Ultrasound 48 (2007) 105-112
17. Bettica P., Cline G., Hart D.J., et al. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 46 (2002) 3178-3184
18. Pastoureau P.C., Chomel A.C., and Bonnet J. Evidence of early subchondral bone changes in the meniscectomized guinea pig. A densitometric study using dual-energy X-ray absorptiometry subregional analysis. Osteoarthritis Cartilage 7 (1999) 466-473
19. Buckland-Wright J.C., Macfarlane D.G., Lynch J.A., and Clark B. Quantitative microfocal radiographic assessment of progression in osteoarthritis of the hand. Arthritis Rheum 33 (1990) 57-65
20. Buckland-Wright J.C., Lynch J.A., and Macfarlane D.G. Fractal signature analysis measures cancellous bone organisation in macroradiographs of patients with knee osteoarthritis. Ann Rheum Dis 55 (1996) 749-755
21. Sharif M., George E., and Dieppe P.A. Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee. Arthritis Rheum 38 (1995) 78-81
22. Dieppe P., Cushnaghan J., Young P., and Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 52 (1993) 557-563
23. McCarthy C., Cushnaghan J., and Dieppe P. The predictive role of scintigraphy in radiographic osteoarthritis of the hand. Osteoarthritis Cartilage 2 (1994) 25-28
24. Gevers G., and Dequeker J. Collagen and non-collagenous protein content (osteocalcin, sialoprotein, proteoglycan) in the iliac crest bone and serum osteocalcin in women with and without hand osteoarthritis. Coll Relat Res 7 (1987) 435-442
25. Dequeker J., Mohan R., Finkelman R.D., et al. Generalized osteoarthritis associated with increased insulin-like growth factor types I and II and transforming growth factor beta in cortical bone from the iliac crest. Possible mechanism of increased bone density and protection against osteoporosis. Arthritis Rheum 36 (1993) 1702-1708
26. Ferguson V.L., Bushby A.J., and Boyde A. Nanomechanical properties and mineral concentration in articular calcified cartilage and subchondral bone. J Anat 203 (2003) 191-202
27. Crane G.J., Fazzalari N.L., Parkinson I.H., and Vernon-Roberts B. Age-related changes in femoral trabecular bone in arthrosis. Acta Orthop Scand 61 (1990) 421-426
28. Fazzalari N.L., and Parkinson I.H. Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. Osteoarthritis Cartilage 6 (1998) 377-382
29. Grynpas M.D., Alpert B., Katz I., et al. Subchondral bone in osteoarthritis. Calcif Tissue Int 49 (1991) 20-26
30. Li B., and Aspden R.M. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res 12 (1997) 641-651
31. Mansell J.P., Tarlton J.F., and Bailey A.J. Biochemical evidence for altered subchondral bone collagen metabolism in osteoarthritis of the hip. Br J Rheumatol 36 (1997) 16-19
32. Mansell J.P., and Bailey A.J. Abnormal cancellous bone collagen metabolism in osteoarthritis. J Clin Invest 101 (1998) 1596-1603
33. Bailey A.J., Sims T.J., and Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type I homotrimer. Int J Biochem Cell Biol 34 (2002) 176-182
34. Gevers G., Dequeker J., Geusens P., et al. Physical and histomorphological characteristics of iliac crest bone differ according to the grade of osteoarthritis at the hand. Bone 10 (1989) 173-177
35. Zysset P.K., Sonny M., and Hayes W.C. Morphology-mechanical property relations in trabecular bone of the osteoarthritic proximal tibia. J Arthroplasty 9 (1994) 203-216
36. Couchourel D., Aubry I., Delalandre A., et al. Altered mineralization of human osteoarthritic osteoblasts is due to abnormal collagen type 1 production. Arthritis Rheum 60 (2009) 1438-1450
37. Hilal G., Martel-Pelletier J., Pelletier J.P., et al. Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: possible role in subchondral bone sclerosis. Arthritis Rheum 41 (1998) 891-899
38. Hilal G., Martel-Pelletier J., Pelletier J.P., et al. Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. Arthritis Rheum 42 (1999) 2112-2122
39. Aspden R.M., Scheven B.A., and Hutchison J.D. Osteoarthritis as a systemic disorder including stromal cell differentiation and lipid metabolism. Lancet 357 (2001) 1118-1120
40. Plumb M.S., and Aspden R.M. High levels of fat and (n - 6) fatty acids in cancellous bone in osteoarthritis. Lipids Health Dis 3 (2004) 12 10.1186/1476-511X-3-12
41. Murphy J.M., Dixon K., Beck S., et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 46 (2002) 704-713
42. Thomas T., Gori F., Khosla S., et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140 (1999) 1630-1638
43. Gordeladze J.O., Drevon C.A., Syversen U., and Reseland J.E. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 85 (2002) 825-836
44. Bennett C.N., Ross S.E., Longo K.A., et al. Regulation of Wnt signaling during a dipogenesis. J Biol Chem 277 (2002) 30998-31004
45. Fox K.E., Colton L.A., Erickson P.F., et al. Regulation of cyclin D1 and Wnt10b gene expression by cAMP-responsive element-binding protein during early adipogenesis involves differential promoter methylation. J Biol Chem 283 (2008) 35096-35105
46. Poole K.E., van Bezooijen R.L., Loveridge N., et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Fed Am Soc Exp Bio J 19 (2005) 1842-1844
47. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., and Lowik C.W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16 (2005) 319-327
48. Couchourel D., Delalandre A., and Lajeunesse D. Increased expression of Wnt inhibitory factors in subchondral osteoblasts from osteoarthritic patients could play a role in their abnormal phenotype and mineralization. Ann Rheum Dis 67 Suppl. II (2008) 98 [abstract]
49. Li X., Liu P., Liu W., et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet 37 (2005) 945-952
50. Robinson J.A., Chatterjee-Kishore M., Yaworsky P.J., et al. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J Biol Chem 281 (2006) 31720-31728
51. Liu J., Zou L., Wang J., et al. Hydrostatic pressure promotes Wnt10b and Wnt4 expression dependent and independent on ERK signaling in early-osteoinduced MSCs. Biochem Biophys Res Commun 379 (2009) 505-509
52. Boyden L.M., Mao J., Belsky J., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 (2002) 1513-1521
53. Little R.D., Carulli J.P., Del Mastro R.G., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 (2002) 11-19
54. Babij P., Zhao W., Small C., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18 (2003) 960-974
55. Hartmann C. A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol 16 (2006) 151-158
56. Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
57. Kato M., Patel M.S., Levasseur R., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157 (2002) 303-314
58. Smith A.J., Gidley J., Sandy J.R., et al. Haplotypes of the low-density lipoprotein receptor-related protein 5 (LRP5) gene: are they a risk factor in osteoarthritis?. Osteoarthritis Cartilage 13 (2005) 608-613
59. Loughlin J., Dowling B., Chapman K., et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci USA 101 (2004) 9757-9762
60. Chung Y.S., Baylink D.J., Srivastava A.K., et al. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res 19 (2004) 1395-1402
61. Li J., Sarosi I., Cattley R.C., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39 (2006) 754-766
62. Morvan F., Boulukos K., Clement-Lacroix P., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21 (2006) 934-945
63. Diarra D., Stolina M., Polzer K., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 (2007) 156-163
64. Gardner J.C., van Bezooijen R.L., Mervis B., et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90 (2005) 6392-6395
65. Winkler D.G., Sutherland M.S., Ojala E., et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280 (2005) 2498-2502
66. Fischer L., Boland G., and Tuan R.S. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells. J Biol Chem 277 (2002) 30870-30878
67. Bain G., Muller T., Wang X., and Papkoff J. Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun 301 (2003) 84-91
68. Zamurovic N., Cappellen D., Rohner D., and Susa M. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J Biol Chem 279 (2004) 37704-37715
69. Massicotte F., Fernandes J.C., Martel-Pelletier J., et al. Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone 38 (2006) 333-341
70. Rydziel S., Delany A.M., and Canalis E. Insulin-like growth factor I inhibits the transcription of collagenase 3 in osteoblast cultures. J Cell Biochem 67 (1997) 176-183
71. van Beuningen H.M., van der Kraan P.M., Arntz O.J., and van den Berg W.B. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 71 (1994) 279-290
72. Scharstuhl A., Glansbeek H.L., van Beuningen H.M., et al. Inhibition of endogenous TGF-beta during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 169 (2002) 507-514
73. Dumond H., Presle N., Terlain B., et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 48 (2003) 3118-3129
74. Darnay B.G., Haridas V., Ni J., et al. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 273 (1998) 20551-20555
75. Gravallese E.M., and Goldring S.R. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43 (2000) 2143-2151
76. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
77. Armstrong A.P., Tometsko M.E., Glaccum M., et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 277 (2002) 44347-44356
78. Kwan Tat S., Padrines M., Theoleyre S., et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 (2004) 49-60
79. Kwan Tat S., Pelletier J.P., Lajeunesse D., et al. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clin Exp Rheumatol 26 (2008) 295-304
80. Zhao C., Irie N., Takada Y., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4 (2006) 111-121
81. Kwan Tat S., Pelletier J.P., Amiable N., et al. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts: a new therapeutic approach. Arthritis Rheum 58 (2008) 3820-3830
82. 2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts. J Bone Miner Res 16 (2001) 713-721
83. Dietrich J.W., Canalis E.M., Maina D.M., and Raisz L.G. Hormonal control of bone collagen synthesis in vitro: effects of parathyroid hormone and calcitonin. Endocrinology 98 (1976) 943-949
84. Beresford J.N., Gallagher J.A., Poser J.W., and Russell R.G. Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab Bone Dis Relat Res 5 (1984) 229-234
85. Coats A.M., Zioupos P., and Aspden R.M. Material properties of subchondral bone from patients with osteoporosis or osteoarthritis by microindentation testing and electron probe microanalysis. Calcif Tissue Int 73 (2003) 66-71
86. Burr D.B. Increased biological activity of subchondral mineralized tissues underlies the progressive deterioration of articular cartilage in osteoarthritis. J Rheumatol 32 (2005) 1156-1158 [discussion 1158-1159]
87. Mital M.A., and Millington P.F. Osseous pathway of nutrition to articular cartilage of the human femoral head. Lancet 1 (1970) 842
88. Mori S., Harruff R., and Burr D.B. Microcracks in articular calcified cartilage of human femoral heads. Arch Pathol Lab Med 117 (1993) 196-198
89. Sokoloff L. Microcracks in the calcified layer of articular cartilage. Arch Pathol Lab Med 117 (1993) 191-195
90. Villanueva A.R., Longo III J.A., and Weiner G. Staining and histomorphometry of microcracks in the human femoral head. Biotech Histochem 69 (1994) 81-88
91. Burr D.B., and Radin E.L. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis?. Rheum Dis Clin North Am 29 (2003) 675-685
92. Laurent U.B., Fraser J.R., Engstrom-Laurent A., et al. Catabolism of hyaluronan in the knee joint of the rabbit. Matrix 12 (1992) 130-136
93. Malinin T., and Ouellette E.A. Articular cartilage nutrition is mediated by subchondral bone: a long-term autograft study in baboons. Osteoarthritis Cartilage 8 (2000) 483-491
94. Huebner J.L., Hanes M.A., Beekman B., et al. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthritis Cartilage 10 (2002) 758-767
95. Radin E.L., and Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 213 (1986) 34-40
96. Carlson C.S., Loeser R.F., Purser C.B., et al. Osteoarthritis in cynomolgus macaques. III: effects of age, gender, and subchondral bone thickness on the severity of disease. J Bone Miner Res 11 (1996) 1209-1217
97. Brandt K.D. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. An animal model of osteoarthritis. Ann NY Acad Sci 732 (1994) 199-205 [Review]
98. Burr D.B. The importance of subchondral bone in osteoarthrosis. Curr Opin Rheumatol 10 (1998) 256-562
99. Burr D.B., and Schaffler M.B. The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence. Microsc Res Tech 37 (1997) 343-357
100. Imhof H., Breitenseher M., Kainberger F., et al. Importance of subchondral bone to articular cartilage in health and disease. Top Magn Reson Imaging 10 (1999) 180-192
101. Kwan Tat S, Amiable N, Pelletier JP, et al. Modulation of OPG, RANK, and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (in press).
102. Kwan Tat S., Pelletier J.P., Amiable N., et al. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes. Arthritis Res Ther 11 (2009) R119
103. Pfander D., Cramer T., Weseloh G., et al. Hepatocyte growth factor in human osteoarthritic cartilage. Osteoarthritis Cartilage 7 (1999) 548-559
104. Blanquaert F., Pereira R.C., and Canalis E. Cortisol inhibits hepatocyte growth factor/scatter factor expression and induces c-met transcripts in osteoblasts. Am J Physiol Endocrinol Metab 278 (2000) E509-E515
105. Guévremont M., Martel-Pelletier J., Massicotte F., et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HGF: potential implication of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res 18 (2003) 1073-1081
106. Reboul P., Pelletier J.P., Tardif G., et al. Hepatocyte growth factor induction of collagenase 3 production in human osteoarthritic cartilage: involvement of the stress-activated protein kinase/c-Jun N-terminal kinase pathway and a sensitive p38 mitogen-activated protein kinase inhibitor cascade. Arthritis Rheum 44 (2001) 73-84
107. Moldovan F., Pelletier J.P., Hambor J., et al. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. Arthritis Rheum 40 (1997) 1653-1661
108. Berthiaume M.J., Raynauld J.P., Martel-Pelletier J., et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 64 (2005) 556-563
109. Bruyere O., Collette J., Kothari M., et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 65 (2006) 1050-1054
110. Jung Y.O., Do J.H., Kang H.J., et al. Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. Clin Exp Rheumatol 24 (2006) 253-259
111. Sharif M., Kirwan J., Charni N., et al. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford) 46 (2007) 938-943
112. Conrozier T., Poole A.R., Ferrand F., et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 26 (2008) 430-435
113. Chaganti R.K., Kelman A., Lui L., et al. Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage 16 (2008) 566-571
114. Hunter D.J., Lavalley M., Li J., et al. Biochemical markers of bone turnover and their association with bone marrow lesions. Arthritis Res Ther 10 (2008) R102
115. Kong S.Y., Stabler T.V., Criscione L.G., et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 54 (2006) 2496-2504
116. Pothacharoen P., Teekachunhatean S., Louthrenoo W., et al. Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients. Osteoarthritis Cartilage 14 (2006) 299-301
117. Jordan K.M., Syddall H.E., Garnero P., et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 65 (2006) 871-877
118. Davis C.R., Karl J., Granell R., et al. Can biochemical markers serve as surrogates for imaging in knee osteoarthritis?. Arthritis Rheum 56 (2007) 4038-4047
119. Meulenbelt I., Kloppenburg M., Kroon H.M., et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage 15 (2007) 379-385
120. Pilichou A., Papassotiriou I., Michalakakou K., et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 41 (2008) 746-749
121. Ling S.M., Patel D.D., Garnero P., et al. Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage 17 (2009) 43-48
122. Cibere J., Zhang H., Garnero P., et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 60 (2009) 1372-1380
123. Kadri A., Ea H.K., Bazille C., et al. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum 58 (2008) 2379-2386
124. Shimizu S., Asou Y., Itoh S., et al. Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 56 (2007) 3358-3365
125. Nakashima T., Wada T., and Penninger J.M. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15 (2003) 280-287
126. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004) 1059-1066
127. Ding M., Danielsen C.C., and Hvid I. The effects of bone remodeling inhibition by alendronate on three-dimensional microarchitecture of subchondral bone tissues in guinea pig primary osteoarthrosis. Calcif Tissue Int 82 (2008) 77-86
128. Meyer J., Farmer R., and Prenger M.C. Risedronate but not alendronate slows disease progression in the guinea pig model of primary osteoarthritis. J Bone Miner Res 5305 (2001) SA472 [abstract]
129. Meyer J.M., Dansereau S.M., Farmer R.W., et al. Bisphosphonates structurally similar to risedronate (actonel) slow disease progression in the guinea pig model of primary osteoarthritis. Arthritis Rheum 44 5307 (2001) 1527 [abstract]
130. Myers S.L., Brandt K.D., Burr D.B., et al. Effects of a bisphosphonate on bone histomorphometry and dynamics in the canine cruciate deficiency model of osteoarthritis. J Rheumatol 26 (1999) 2645-2653
131. Spector T.D., Conaghan P.G., Buckland-Wright J.C., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 7 (2005) R625-R633
132. Bingham III C.O., Buckland-Wright J.C., Garnero P., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54 (2006) 3494-3507
133. Hott M., Deloffre P., Tsouderos Y., and Marie P.J. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 33 (2003) 115-123
134. Marie P.J., Hott M., Modrowski D., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 8 (1993) 607-615
135. Ammann P., Shen V., Robin B., et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19 (2004) 2012-2020
136. Buehler J., Chappuis P., Saffar J.L., et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 29 (2001) 176-179
137. Delannoy P., Bazot D., and Marie P.J. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 51 (2002) 906-911
138. Barbara A., Delannoy P., Denis B.G., and Marie P.J. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism 53 (2004) 532-537
139. Baron R., and Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 450 (2002) 11-17
140. Canalis E., Hott M., Deloffre P., et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18 (1996) 517-523
141. Fromigue O., Hay E., Barbara A., et al. Calcium sensing receptor-dependent and -independent activation of osteoblast replication and survival by strontium ranelate. J Cell Mol Med (2009) [epub ahead of print]
142. Takahashi N., Sasaki T., Tsouderos Y., and Suda T.S. 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18 (2003) 1082-1087
143. Papaioannou N.A., Triantafillopoulos I.K., Khaldi L., et al. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage 15 (2007) 386-395
144. Manicourt D.H., Altman R.D., Williams J.M., et al. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 42 (1999) 1159-1167
145. El Hajjaji H., Williams J.M., Devogelaer J.P., et al. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 12 (2004) 904-911
146. Manicourt D.H., Azria M., Mindeholm L., et al. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54 (2006) 3205-3211
147. Konttinen Y.T., Mandelin J., Li T.F., et al. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum 46 (2002) 953-960
148. Kafienah W., Bromme D., Buttle D.J., et al. Human cathepsin K cleaves native type I and II collagens at the N- terminal end of the triple helix. Biochem J 331 Pt 3 (1998) 727-732
149. Sniekers Y.H., Weinans H., Bierma-Zeinstra S.M., et al. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage 16 (2008) 533-541
150. Karsdal M.A., Byrjalsen I., Leeming D.J., and Christiansen C. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord 9 (2008) 153 10.1186/1471-2474-9-153
151. Christgau S., and Cloos P.A. Sex hormones in the regulation of bone and cartilage metabolism: an old paradigm and a new challenge. Minerva Ginecol 57 (2005) 611-617
152. Tetlow L.C., and Woolley D.E. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 9 (2001) 423-431
153. McAlindon T.E., Felson D.T., Zhang Y., et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 125 (1996) 353-359
154. Lane N.E., Gore L.R., Cummings S.R., et al. Serum vitamin D levels and incident changes of radiographic hip osteoarthritis: a longitudinal study. Study of Osteoporotic Fractures Research Group. Arthritis Rheum 42 (1999) 854-860
155. Felson D.T., Niu J., Clancy M., et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum 56 (2007) 129-136
156. Hunter D.J., Hart D., Snieder H., et al. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) 42 (2003) 1311-1316
157. Ding C., Cicuttini F., Parameswaran V., et al. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum 60 (2009) 1381-1389
158. Dougados M., Nguyen M., Berdah L., et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 44 (2001) 2539-2547
159. Pelletier J.P., Lajeunesse D., Reboul P., et al. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol 28 (2001) 814-824
160. Boileau C., Tat S.K., Pelletier J.P., et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther 10 (2008) R71
161. Boileau C., Martel-Pelletier J., Caron C., et al. Protective effects of total fraction of avocado/soybean unsaponifiables (ASU) on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and MMP-13. Arthritis Res Ther 11 (2009) R41 10.1186/ar2649
162. Kawcak C.E., Frisbie D.D., McIlwraith C.W., et al. Evaluation of avocado and soybean unsaponifiable extracts for treatment of horses with experimentally induced osteoarthritis. Am J Vet Res 68 (2007) 598-604
163. Cake M.A., Read R.A., Guillou B., and Ghosh P. Modification of articular cartilage and subchondral bone pathology in an ovine meniscectomy model of osteoarthritis by avocado and soya unsaponifiables (ASU). Osteoarthritis Cartilage 8 (2000) 404-411
164. Maheu E., Mazieres B., Valat J.P., et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 41 (1998) 81-91
165. Lequesne M., Maheu E., Cadet C., and Dreiser R.L. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 47 (2002) 50-58
166. Wang S.X., Laverty S., Dumitriu M., et al. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum 56 (2007) 1537-1548
167. Tat S.K., Pelletier J.P., Vergés J., et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts. Arthritis Res Ther 9 (2007) R117
168. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. J Am Med Assoc 283 (2000) 1469-1475
169. Richy F., Bruyere O., Ethgen O., et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163 (2003) 1514-1522